Patents by Inventor Carlos A. Guzman

Carlos A. Guzman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12042536
    Abstract: The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.
    Type: Grant
    Filed: January 19, 2023
    Date of Patent: July 23, 2024
    Assignees: The Governors of the University of Alberta, Helmholtz Center for Infection Research
    Inventors: Michael Houghton, Abdolamir Landi, Carlos A. Guzman, Thomas Ebensen, Darren Hockman, John L. Law, Michael Logan
  • Publication number: 20240058438
    Abstract: The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.
    Type: Application
    Filed: January 19, 2023
    Publication date: February 22, 2024
    Inventors: Michael Houghton, Abdolamir Landi, Carlos A. Guzman, Thomas Ebensen, Darren Hockman, John L. Law, Michael Logan
  • Publication number: 20230129118
    Abstract: Phytosphingosine derivatives suitable as adjuvants in immune stimulation, pharmaceutical compositions comprising such compounds and the medical use of the compounds and/or compositions in therapeutic or prophylactic methods of immune stimulation in a subject, and for use in the treatment of a disease, for which stimulation of an immune response in a subject produces a therapeutic benefit. The phytosphingosine derivative may also be used as adjuvants in vaccinating a subject. The phytosphingosine derivative may also be used in stimulating antibody production, stimulating an immune response against infection, stimulating an immune response against a cancer, or preventing and/or treating septic shock. Methods for the manufacture of the derivatives comprising an Ugi-4-component reaction (Ugi-4CR) is also disclosed.
    Type: Application
    Filed: June 18, 2021
    Publication date: April 27, 2023
    Inventors: Yanira MENDEZ-GOMEZ, Bernhard WESTERMANN, Daniel GARCIA-RIVERA, Aldrin VASCO-VIDAL, Ludger WESSJOHANN, Carlos A. GUZMÁN, Thomas EBENSEN, Kai SCHULZE, Peggy RIESE, Stephanie TRITTEL
  • Patent number: 11576968
    Abstract: The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.
    Type: Grant
    Filed: December 15, 2020
    Date of Patent: February 14, 2023
    Assignee: The Governors of the University of Alberta
    Inventors: Michael Houghton, Abdolamir Landi, Carlos A. Guzman, Thomas Ebensen, Darren Hockman, John L. Law, Michael Logan
  • Publication number: 20220257752
    Abstract: In a first aspect, the present invention relates to cyclic dinucleotide compounds, in particular, c-di AMP for use in a method of inducing or promoting an immune response in an individual wherein said individual is a neonate or infant. The compound according to the present invention is particularly useful for use in therapeutic or prophylactic vaccination. In a further aspect, pharmaceutical compositions comprising the compound according to the present invention as an adjuvant, a pharmaceutically active ingredient for use as defined herein, in particular, as an adjuvant in a vaccine for unborn children, neonates and infants are provided. Finally, the present invention relates to a kit comprising a compound according to the present invention as an adjuvant, an antigen comprising antigenic structure as active vaccination component, in particular, to the use of said kit in a use of preventing or treating a disease.
    Type: Application
    Filed: August 28, 2020
    Publication date: August 18, 2022
    Inventors: Carlos A. GUZMAN, Dario LIRUSSI, Thomas EBENSEN, Sebastian Felix WEISSMANN
  • Publication number: 20210170018
    Abstract: The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.
    Type: Application
    Filed: December 15, 2020
    Publication date: June 10, 2021
    Inventors: Michael Houghton, Abdolamir Landi, Carlos A. Guzman, Thomas Ebensen, Darren Hockman, John L. Law, Michael Logan
  • Publication number: 20210030865
    Abstract: In a first aspect, the present invention relates to a method for determining the responsiveness of an individual to vaccination, like viral vaccination or for the determination of viral vaccine efficacy in an individual as well as a method for the stratification of the vaccination regimen, e.g. viral vaccination, in an individual based on determining the level or the amount of at least one of IL-8 or IL-18 in a sample; said sample is obtained from an individual at least once before or at least once after vaccination. The method allows to determine the vaccination regimen with the vaccine, in particular, a virus vaccine, like an influenza virus vaccine whereby when a low level of at least one of IL-8 and/or IL-18 is determined, said low level is indicative for a personalized vaccine strategy. In a further aspect, the use of at least one of IL-8 or IL-18 as a predictive marker for vaccine efficacy or immune protection by vaccination is provided.
    Type: Application
    Filed: March 20, 2019
    Publication date: February 4, 2021
    Inventors: Carlos A. GUZMAN, Frank PESSLER, Peggy RIESE, Manas AKMATOV
  • Patent number: 10881726
    Abstract: The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: January 5, 2021
    Assignees: The Governors of the University of Alberta, Helmholtz Center for Infection Research
    Inventors: Michael Houghton, Abdolamir Landi, Carlos A. Guzman, Thomas Ebensen, Darren Hockman, John L. Law, Michael Logan
  • Patent number: 9597391
    Abstract: The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new compounds useful as adjuvants and/or immunomodulators for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumors, allergies as well as for the control of fertility in human or animal populations. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants. In addition, the invention relates to its uses as active ingredients in pharmaceutical compositions.
    Type: Grant
    Filed: November 8, 2006
    Date of Patent: March 21, 2017
    Assignee: HELMHOLTZ_ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH
    Inventors: Thomas Ebensen, Michael Morr, Carlos A. Guzman
  • Patent number: 8257734
    Abstract: The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new compounds useful as adjuvants and/or immunomodulators for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumors, allergies as well as for the control of fertility in human or animal populations. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants. In addition, the invention relates to its uses as active ingredients in pharmaceutical compositions.
    Type: Grant
    Filed: November 8, 2006
    Date of Patent: September 4, 2012
    Assignee: Helmhotlz-Zentrum Fuer Infektions-Forschung GmbH
    Inventors: Thomas Ebensen, Michael Morr, Carlos A. Guzman
  • Publication number: 20100015215
    Abstract: The present invention relates to adjuvants of the glycolipid type and their uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new uses of compounds useful as adjuvants for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumours and allergies. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants.
    Type: Application
    Filed: September 6, 2007
    Publication date: January 21, 2010
    Inventors: Thomas Ebensen, Michael Morr, Carlos A. Guzman, Götz Milkereit
  • Publication number: 20090169609
    Abstract: The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new compounds useful as adjuvants and/or immunomodulators for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumours, allergies as well as for the control of fertility in human or animal populations. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants. In addition, the invention relates to its uses as active ingredients in pharmaceutical compositions.
    Type: Application
    Filed: November 8, 2006
    Publication date: July 2, 2009
    Applicant: HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMGB
    Inventors: Thomas Ebensen, Michael Morr, Carlos A. Guzman
  • Publication number: 20080286296
    Abstract: The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new compounds useful as adjuvants and/or immunomodulators for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumors, allergies as well as for the control of fertility in human or animal populations. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants. In addition, the invention relates to its uses as active ingredients in pharmaceutical compositions.
    Type: Application
    Filed: November 8, 2006
    Publication date: November 20, 2008
    Inventors: Thomas Ebensen, Michael Morr, Carlos A. Guzman
  • Publication number: 20080206319
    Abstract: The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new compounds useful as adjuvants for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumours, allergies as well as for the control of fertility in human or animal populations. The compounds are particularly useful not only as systemic, but preferably as mucosal adjuvants. In addition, the invention relates to its uses as active ingredients in pharmaceutical compositions.
    Type: Application
    Filed: October 19, 2006
    Publication date: August 28, 2008
    Inventors: Thomas Ebensen, Michael Morr, Carlos A. Guzman
  • Patent number: 7115269
    Abstract: The present invention is directed to an attenuated Salmonella comprising a eukaryotic expression vector for delivery of the eukaryotic expression vector to a eukaryotic cell. Delivery may be to eukaryotic cells cultured in vitro or to cells in vivo, such as by oral administration of the attenuated Salmonella comprising the eukaryotic expression vector.
    Type: Grant
    Filed: October 18, 1999
    Date of Patent: October 3, 2006
    Assignee: Gesellschaft fuer Biotechnologische Forschung mbH (GBF)
    Inventors: Ayub Darji, Carlos A. Guzman, Kenneth Timmis, Siegfried Weiss, Birgit Gerstel, Trinad Chakraborty, Petra Wachholz, Jürgen Wehland
  • Publication number: 20020106376
    Abstract: A common problem in human vaccinology is the limited availability of efficient and non-toxic adjuvants capable of promoting mucosal responses. The potential usefulness of fibronectin-binding protein (SfbI) of Streptococcus pyogenes as immunological adjuvant was assessed using ovalbumin (OVA) as a model antigen. Mice were immunized by intranasal route either with soluble OVA or OVA covalently coupled to SfbI. Immunization with OVA-SfbI resulted in the elicitation of about 100-fold higher titres of anti-OVA serum IgG than using OVA alone. The anti-OVA IgG subclass pattern was dominated in both groups of mice by IgG1, followed by IgG2b, IgG2a, and IgG3. Immunization with OVA-SfbI also resulted in the elicitation of OVA-specific IgA in lung washes (24% of the total IgA), which was absent in mice immunized with OVA alone. Spleen cells from OVA-SfbI immunized mice also gave a much stronger proliferative response to in vitro restimulation with soluble OVA.
    Type: Application
    Filed: January 30, 2002
    Publication date: August 8, 2002
    Applicant: Gesellschaft fuer Biotechnologische Forschung mbH (GBF)
    Inventors: Eva Medina, Gursharan S. Chhatwal, Carlos A. Guzman